A european Phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Minalcipran for the treatment of the Fibromyalgia Syndrome
A european Phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Minalcipran for the treatment of the Fibromyalgia Syndrome
A european Phase III, multicentre, double-blind, randomised, monotherapy, 12-month study of Minalcipran for the treatment of the Fibromyalgia Syndrome
Therapeutic area :
Central Nervous System
Disease :
Fibromyalgia
Study medication :
Milnacipran
Phase :
Phase III
Start Date :
19 September 2006
End date :
02 October 2008
Study ID :
F02207 GE 304
EudraCT/CTIS number :
2006-001230-41
Send by email